AVDL
Avadel Pharmaceuticals PLC
Price Chart
No historical data available
Latest Quote
$21.64
+0.00 (+0.00%)
Current Price
| Previous Close | $21.64 |
| Open | $21.65 |
| Day High | $21.76 |
| Day Low | $21.63 |
| Volume | 34,980,925 |
Stock Information
| Shares Outstanding | 98.15M |
| Total Debt | $37.38M |
| Cash Equivalents | $91.58M |
| Revenue | $248.52M |
| Net Income | $-278K |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2.12B |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
đ° Latest News
3 European Stocks Estimated To Be Trading Up To 48.2% Below Intrinsic Value
Simply Wall St. âĸ 2026-02-16T10:37:54Z
Alkermes Completes Acquisition of Avadel
MT Newswires âĸ 2026-02-12T13:57:34ZBlackRock, Inc. (BLK) to Invest $333.6M in Indiaâs Aditya Birla Renewables Limited
Insider Monkey âĸ 2026-01-16T15:26:50Z
Rechecking Avadel Pharmaceuticals (AVDL) Valuation After Strong Share Price Momentum
Simply Wall St. âĸ 2026-01-14T02:13:38Z
Do Options Traders Know Something About Avadel Pharmaceuticals Stock We Don't?
Zacks âĸ 2026-01-09T13:32:00Z
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data
Simply Wall St. âĸ 2026-01-07T07:09:15Z
Assessing Avadel Pharmaceuticals (AVDL) Valuation After Strong 1-Year Share Price Performance
Simply Wall St. âĸ 2025-12-20T16:07:31Z
How Recent Deal Developments Are Reshaping The Avadel Pharmaceuticals Investment Story
Simply Wall St. âĸ 2025-12-06T00:20:59Z
Has Avadelâs 115% Rally in 2024 Already Priced In Its Narcolepsy Breakthrough?
Simply Wall St. âĸ 2025-12-05T23:13:52Z
Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge
Simply Wall St. âĸ 2025-11-30T11:09:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $15,277,000 | $846,000 | $0 | $0 |
| Cost Of Revenue | $15,277,000 | $846,000 | $0 | $0 |
| Total Revenue | $169,117,000 | $27,963,000 | $0 | $0 |
| Operating Revenue | $169,117,000 | $27,963,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $10,830,000 | $9,886,000 | $12,342,000 | $9,942,000 |
| Total Expenses | $211,516,000 | $165,812,000 | $95,216,000 | $85,599,000 |
| Other Income Expense | $4,150,000 | $-13,042,000 | $-3,881,000 | $2,396,000 |
| Net Non Operating Interest Income Expense | $-10,830,000 | $-9,886,000 | $-12,342,000 | $-9,942,000 |
| Interest Expense Non Operating | $10,830,000 | $9,886,000 | $12,342,000 | $9,942,000 |
| Operating Expense | $196,239,000 | $164,966,000 | $95,216,000 | $85,599,000 |
| Other Non Operating Income Expenses | - | - | - | $217,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Net Interest Income | $-10,830,000 | $-9,886,000 | $-12,342,000 | $-9,942,000 |
| Normalized Income | $-52,961,114 | $-147,274,640 | $-134,398,010 | $-79,318,160 |
| Net Income From Continuing And Discontinued Operation | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Total Operating Income As Reported | $-42,399,000 | $-137,849,000 | $-98,561,000 | $-85,546,000 |
| Net Income Common Stockholders | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Net Income | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Net Income Including Noncontrolling Interests | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Net Income Continuous Operations | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Pretax Income | $-49,079,000 | $-160,777,000 | $-111,439,000 | $-93,145,000 |
| Special Income Charges | $0 | $-13,129,000 | $-3,345,000 | $53,000 |
| Operating Income | $-42,399,000 | $-137,849,000 | $-95,216,000 | $-85,599,000 |
| Gross Profit | $153,840,000 | $27,117,000 | $0 | $0 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $0 |
| Depreciation And Amortization In Income Statement | - | - | - | $0 |
| Amortization Of Intangibles Income Statement | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.51 | $-2.00 | $-2.29 | $-1.32 |
| Basic EPS | $-0.51 | $-2.00 | $-2.29 | $-1.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $20,886 | $-40,640 | $-815,010 | $406,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-39,718,000 | $-136,083,000 | $-93,723,000 | $-84,784,000 |
| Total Unusual Items | $4,150,000 | $-13,042,000 | $-3,881,000 | $2,396,000 |
| Total Unusual Items Excluding Goodwill | $4,150,000 | $-13,042,000 | $-3,881,000 | $2,396,000 |
| Reconciled Depreciation | $2,681,000 | $1,766,000 | $1,493,000 | $815,000 |
| EBITDA (Bullshit earnings) | $-35,568,000 | $-149,125,000 | $-97,604,000 | $-82,388,000 |
| EBIT | $-38,249,000 | $-150,891,000 | $-99,097,000 | $-83,203,000 |
| Diluted Average Shares | $95,141,000 | $80,174,000 | $60,094,000 | $58,535,000 |
| Basic Average Shares | $95,141,000 | $80,174,000 | $60,094,000 | $58,535,000 |
| Diluted NI Availto Com Stockholders | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Tax Provision | $-247,000 | $-501,000 | $26,025,000 | $-15,816,000 |
| Restructuring And Mergern Acquisition | $0 | $0 | $3,345,000 | $-53,000 |
| Gain On Sale Of Security | $4,150,000 | $87,000 | $-536,000 | $2,343,000 |
| Research And Development | $15,196,000 | $13,261,000 | $20,700,000 | $17,104,000 |
| Selling General And Administration | $181,043,000 | $151,705,000 | $74,516,000 | $68,495,000 |
| Other Special Charges | - | $13,129,000 | - | - |
| Gain On Sale Of Business | - | - | - | $0 |
| Amortization | - | - | - | $0 |
Fetched: 2026-02-13
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $57,012,000 | $70,903,000 | $-37,981,000 | $61,408,000 |
| Total Assets | $164,236,000 | $164,698,000 | $132,785,000 | $247,265,000 |
| Total Non Current Assets | $30,028,000 | $30,496,000 | $31,942,000 | $54,775,000 |
| Other Non Current Assets | $337,000 | $579,000 | $636,000 | $1,100,000 |
| Goodwill And Other Intangible Assets | $16,836,000 | $16,836,000 | $16,836,000 | $16,836,000 |
| Current Assets | $134,208,000 | $134,202,000 | $100,843,000 | $192,490,000 |
| Other Current Assets | $882,000 | $2,235,000 | $573,000 | $550,000 |
| Prepaid Assets | $5,154,000 | $4,373,000 | $1,523,000 | $3,179,000 |
| Inventory | $20,298,000 | $10,380,000 | $0 | - |
| Receivables | $34,097,000 | $12,103,000 | $2,248,000 | $31,540,000 |
| Accounts Receivable | $34,097,000 | $12,103,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $73,777,000 | $105,111,000 | $96,499,000 | $157,221,000 |
| Cash And Cash Equivalents | $51,371,000 | $31,167,000 | $73,981,000 | $50,708,000 |
| Non Current Accounts Receivable | - | $332,000 | $1,232,000 | $1,225,000 |
| Taxes Receivable | - | $1,322,000 | $2,248,000 | $31,540,000 |
| Non Current Deferred Assets | - | - | $0 | $24,128,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $24,128,000 |
| Debt | ||||
| Total Debt | $1,704,000 | $2,624,000 | $131,022,000 | $145,004,000 |
| Long Term Debt And Capital Lease Obligation | $1,122,000 | $1,690,000 | $92,394,000 | $144,104,000 |
| Current Debt And Capital Lease Obligation | $582,000 | $934,000 | $38,628,000 | $900,000 |
| Net Debt | - | - | $55,301,000 | $91,689,000 |
| Long Term Debt | - | - | $91,614,000 | $142,397,000 |
| Current Debt | - | - | $37,668,000 | - |
| Other Current Borrowings | - | - | $37,668,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $90,388,000 | $76,959,000 | $153,930,000 | $169,021,000 |
| Total Non Current Liabilities Net Minority Interest | $41,554,000 | $40,104,000 | $98,137,000 | $148,021,000 |
| Other Non Current Liabilities | $35,281,000 | $33,007,000 | $497,000 | $3,917,000 |
| Tradeand Other Payables Non Current | $5,151,000 | $5,407,000 | $5,246,000 | - |
| Current Liabilities | $48,834,000 | $36,855,000 | $55,793,000 | $21,000,000 |
| Other Current Liabilities | $273,000 | $261,000 | $292,000 | $350,000 |
| Payables And Accrued Expenses | $27,246,000 | $24,124,000 | $15,260,000 | $16,583,000 |
| Payables | $9,218,000 | $12,163,000 | $7,890,000 | $7,679,000 |
| Other Payable | $1,890,000 | $730,000 | - | - |
| Accounts Payable | $7,328,000 | $11,433,000 | $7,890,000 | $7,679,000 |
| Interest Payable | - | $0 | $1,649,000 | $4,920,000 |
| Equity | ||||
| Common Stock Equity | $73,848,000 | $87,687,000 | $-21,150,000 | $78,239,000 |
| Total Equity Gross Minority Interest | $73,848,000 | $87,739,000 | $-21,145,000 | $78,244,000 |
| Stockholders Equity | $73,848,000 | $87,739,000 | $-21,145,000 | $78,244,000 |
| Gains Losses Not Affecting Retained Earnings | $-24,580,000 | $-23,167,000 | $-26,341,000 | $-23,940,000 |
| Other Equity Adjustments | $-24,580,000 | $-23,167,000 | $-26,341,000 | $-23,940,000 |
| Retained Earnings | $-794,328,000 | $-745,496,000 | $-585,220,000 | $-447,756,000 |
| Preferred Stock Equity | - | $52,000 | $5,000 | $5,000 |
| Other | ||||
| Ordinary Shares Number | $96,518,000 | $89,825,000 | $62,878,000 | $58,620,000 |
| Share Issued | $96,518,000 | $89,825,000 | $62,878,000 | $58,620,000 |
| Tangible Book Value | $57,012,000 | $70,851,000 | $-37,986,000 | $61,403,000 |
| Invested Capital | $73,848,000 | $87,687,000 | $108,132,000 | $220,636,000 |
| Working Capital | $85,374,000 | $97,347,000 | $45,050,000 | $171,490,000 |
| Capital Lease Obligations | $1,704,000 | $2,624,000 | $1,740,000 | $2,607,000 |
| Total Capitalization | $73,848,000 | $87,739,000 | $70,469,000 | $220,641,000 |
| Additional Paid In Capital | $891,791,000 | $855,452,000 | $589,783,000 | $549,349,000 |
| Capital Stock | $965,000 | $950,000 | $633,000 | $591,000 |
| Common Stock | $965,000 | $898,000 | $628,000 | $586,000 |
| Preferred Stock | $0 | $52,000 | $5,000 | $5,000 |
| Long Term Capital Lease Obligation | $1,122,000 | $1,690,000 | $780,000 | $1,707,000 |
| Current Capital Lease Obligation | $582,000 | $934,000 | $960,000 | $900,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,515,000 | $7,492,000 | $1,613,000 | $3,167,000 |
| Current Provisions | $14,218,000 | $4,044,000 | - | $217,000 |
| Current Accrued Expenses | $18,028,000 | $11,961,000 | $7,370,000 | $8,904,000 |
| Goodwill | $16,836,000 | $16,836,000 | $16,836,000 | $16,836,000 |
| Net PPE | $12,855,000 | $13,081,000 | $13,238,000 | $11,486,000 |
| Accumulated Depreciation | $-1,013,000 | $-881,000 | $-627,000 | $-465,000 |
| Gross PPE | $13,868,000 | $13,962,000 | $13,865,000 | $11,951,000 |
| Other Properties | $12,402,000 | $12,496,000 | $12,399,000 | $11,201,000 |
| Machinery Furniture Equipment | $1,466,000 | $1,466,000 | $1,466,000 | $750,000 |
| Finished Goods | $10,136,000 | $3,052,000 | - | - |
| Work In Process | $4,963,000 | $2,037,000 | - | - |
| Raw Materials | $5,199,000 | $5,291,000 | - | - |
| Other Short Term Investments | $22,406,000 | $73,944,000 | $22,518,000 | $106,513,000 |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-02-13
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-46,907,000 | $-128,511,000 | $-71,020,000 | $-77,336,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-46,907,000 | $-128,511,000 | $-70,304,000 | $-77,310,000 |
| Cash Flow From Continuing Operating Activities | $-46,907,000 | $-128,511,000 | $-70,304,000 | $-77,310,000 |
| Operating Gains Losses | - | $13,129,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $51,780,000 | $-50,093,000 | $79,698,000 | $56,929,000 |
| Cash Flow From Continuing Investing Activities | $51,780,000 | $-50,093,000 | $79,698,000 | $56,929,000 |
| Capital Expenditure | - | - | $-716,000 | $-26,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,250,000 | $146,064,000 | $25,318,000 | $0 |
| Financing Cash Flow | $15,970,000 | $135,335,000 | $14,543,000 | $263,000 |
| Cash Flow From Continuing Financing Activities | $15,970,000 | $135,335,000 | $14,543,000 | $263,000 |
| Net Common Stock Issuance | $9,250,000 | $146,064,000 | $25,318,000 | $0 |
| Common Stock Issuance | $9,250,000 | $146,064,000 | $25,318,000 | $0 |
| Net Other Financing Charges | - | $25,643,000 | $-4,804,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $-38,665,000 | $-8,653,000 | $0 |
| Interest Paid Supplemental Data | $7,181,000 | $5,250,000 | $9,660,000 | $6,469,000 |
| End Cash Position | $51,371,000 | $31,167,000 | $73,981,000 | $50,708,000 |
| Beginning Cash Position | $31,167,000 | $73,981,000 | $50,708,000 | $71,722,000 |
| Effect Of Exchange Rate Changes | $-639,000 | $455,000 | $-664,000 | $-896,000 |
| Changes In Cash | $20,843,000 | $-43,269,000 | $23,937,000 | $-20,118,000 |
| Proceeds From Stock Option Exercised | $6,720,000 | $2,293,000 | $2,682,000 | $263,000 |
| Net Issuance Payments Of Debt | $0 | $-38,665,000 | $-8,653,000 | $0 |
| Net Long Term Debt Issuance | $0 | $-38,665,000 | $-8,653,000 | $0 |
| Long Term Debt Payments | $0 | $-38,665,000 | $-8,653,000 | $0 |
| Net Investment Purchase And Sale | $51,780,000 | $-50,093,000 | $80,414,000 | $40,455,000 |
| Sale Of Investment | $327,781,000 | $187,136,000 | $83,828,000 | $102,224,000 |
| Purchase Of Investment | $-276,001,000 | $-237,229,000 | $-3,414,000 | $-61,769,000 |
| Net PPE Purchase And Sale | $0 | $0 | $-716,000 | $-26,000 |
| Purchase Of PPE | $0 | $0 | $-716,000 | $-26,000 |
| Change In Working Capital | $-20,315,000 | $-2,999,000 | $24,535,000 | $3,695,000 |
| Change In Other Working Capital | $-1,849,000 | $2,354,000 | $-3,534,000 | $-3,789,000 |
| Change In Payables And Accrued Expense | $12,331,000 | $18,437,000 | $-2,881,000 | $5,127,000 |
| Change In Accrued Expense | $16,424,000 | $16,892,000 | $227,000 | $895,000 |
| Change In Payable | $-4,093,000 | $1,545,000 | $-3,108,000 | $4,232,000 |
| Change In Account Payable | $-4,093,000 | $1,545,000 | $-3,108,000 | $4,232,000 |
| Change In Prepaid Assets | $416,000 | $-2,155,000 | $30,950,000 | $-439,000 |
| Change In Inventory | $-9,219,000 | $-9,532,000 | $0 | $0 |
| Change In Receivables | $-21,994,000 | $-12,103,000 | $0 | $2,796,000 |
| Changes In Account Receivables | $-21,994,000 | $-12,103,000 | $0 | $0 |
| Other Non Cash Items | $-828,000 | $4,058,000 | $8,094,000 | $2,303,000 |
| Stock Based Compensation | $20,387,000 | $15,811,000 | $7,013,000 | $8,872,000 |
| Deferred Tax | $0 | $0 | $26,025,000 | $-15,666,000 |
| Deferred Income Tax | $0 | $0 | $26,025,000 | $-15,666,000 |
| Depreciation Amortization Depletion | $2,681,000 | $1,766,000 | $1,493,000 | $815,000 |
| Depreciation And Amortization | $2,681,000 | $1,766,000 | $1,493,000 | $815,000 |
| Net Income From Continuing Operations | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 |
| Income Tax Paid Supplemental Data | - | $0 | - | $76,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $16,500,000 |
| Sale Of Business | - | $0 | $0 | $16,500,000 |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |
Fetched: 2026-02-13